直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 117802
著者
Sezai, Akira Nihon University
Tanaka, Atsushi Saga University
Imai, Takumi Osaka Metropolitan University
Kida, Keisuke St. Marianna University School of Medicine
Sekino, Hisakuni Sekino Hospital
Murohara, Toyoaki Nagoya University
Suzuki, Norio St. Marianna University School of Medicine
Node, Koichi Saga University
キーワード
sodium–glucose transporter 2 inhibitors
diabetes
heart failure
NT-proBNP
BMI
資料タイプ
学術雑誌論文
抄録
Background: We present results of a 24-week comparative study of the effects of the sodium–glucose cotransporter 2 (SGLT2) inhibitor canagliflozin vs. the sulfonylurea glimepiride, by baseline body mass index (BMI), in patients with type 2 diabetes and chronic heart failure. Methods: We conducted a post hoc analysis of the CANDLE trial. This subanalysis evaluated NT-proBNP, BMI, and other laboratory parameters, according to the subgroups stratified by BMI ≥ 25 kg/m2 vs. BMI < 25 kg/m2. Results: A group ratio of proportional changes in the geometric means of NT-proBNP was 0.99 (p = 0.940) for the subgroup with BMI ≥ 25 kg/m2 and 0.85 (p = 0.075) for the subgroup with BMI < 25 kg/m2, respectively. When baseline BMI was modeled as a continuous variable, results for patients with BMI < 30 kg/m2 showed a slightly smaller increase in NT-proBNP in the canagliflozin group vs. the glimepiride group (p = 0.295); that difference was not seen among patients with BMI ≥30 kg/m2 (p = 0.948). Irrespective of obesity, the canagliflozin group was associated with significant reduction in BMI compared to the glimepiride group. Conclusion: There was no significant difference in the effects of canagliflozin, relative to glimepiride, on NT-proBNP concentrations irrespective of baseline obesity. UMIN clinical trial registration number: UMIN000017669.
掲載誌名
Biomedicines
ISSN
22279059
出版者
MDPI
10
7
開始ページ
1656
発行日
2022-07-09
権利情報
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系